Curaleaf Holdings Inc (CURA.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA.TO)

13.29

-0.33 (2.42%)

as of Sep 11, 2026, 8:00:01 pm Market Open.

119 watching

Investor Insights

Sep 12, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA-T) has generated mixed sentiment among experts, primarily due to its volatility and the uncertain regulatory environment surrounding cannabis in the U.S. While there was a notable spike in interest last year, attributed to potential rescheduling of cannabis that could alleviate tax burdens, the timing of such changes remains unpredictable. Analysts acknowledge CURA's leadership in a growing sector alongside Trulieve, yet express caution, suggesting that even with rescheduling, the stock's returns may revert to previous lows. They emphasize that the cannabis industry is heavily influenced by political dynamics, with tax restrictions on business activities currently limiting growth. Nonetheless, experts recognize improvements in company balance sheets and management, hinting at potential long-term appreciation despite ongoing market volatility.

Consensus

Cautious

Valuation

Undervalued

Similar

Trulieve,TCNNF

RISKY

Big spike last year due to excitement about cannabis being rescheduled, which would reduce its tax bill. It will happen, but hard to predict when (lots of false starts). Volatile. Small position only until cashflow improves.

COMMENT

CURA vs. TRUL re: US reclassification of cannabis

They're leaders in this sector which is playing off this rescheduling. Even without that, these names will do fine, but return to their lows.

WATCH

Entire sector is extremely volatile, trades on politics. Continues to grow and expand in the US. Challenge in US right now is the tax restriction on expensing business activities, and at some point that will change. Challenge is to know when that day will come.

HOLD

Sector as a whole has really improved, and no one's really paying attention. All balance sheets have been cleaned up with better management in place. Lots of room to get more attention, and the space will be volatile. Still a commodity-type play. Undervalued. He'd hold on.

Premium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

And now for something completely risky. Though listed on the TSX, this is an American company that produces weed in that country and across Europe. As everyone knows, U.S. states have been legalizing ganja for several years and there's always speculation of whether this president or that will legalize weed for the entire country. At the end of September, Trump posted that CDB has health benefits an CURA shores skyrocketed over 30%, though they lost roughly half that the next day.

SELL

He has no exposure in the sector. In a holding pattern. Needs the catalysts of legalization and updated banking practices for tax write offs. But who knows how long this might take. Move on.

RISKY

Large issue with the company is legalizing the products(marijuana). Another worry is the over supply of products in the market. Federal laws against marijuana in USA make it hard to deal with expenses that are not deductible (100% tax rate). Could be a good investment if US legislation changes. In the meantime, would not recommend investing.

TRADE

US rescheduling hasn't happened. Off peak. Fits and starts when there's news. Entrenched opposition. US firms can't deduct expenses like a "legitimate" business, so can't turn a profit. Trader's dream, but not for long term.

DON'T BUY

He deals with 3- to 5-year money, holds it a long time, and rides the growth of the underlying business. Canadian marijuana space is at risk. US landscape is more fertile, better capitalized, better opportunities, and more upside, especially when the US legislation becomes law.

DON'T BUY

Getting more liberalization of cannabis laws state by state in US. Good for multi-state operators like this one. Well positioned. Elephant in room is federal tax laws, but tax relief won't be for a while.

BUY

Allan Tong’s Discover Picks Despite inflation, Curaleaf’s Q2 was rosy with revenue growing 8% to $338 million and adjusted EBITDA rising 2.2% to 25.6% following -1.5% in Q1. Also, management lowered 2022 guidance by cutting capital spending by $25 million to $125 million. Caveats: There’s a lot of competition in any of these territories, so establishing a presence in all corners of the U.S. is crucial. Also, the path to legalization will be unpredictable, given the vagaries of American politics. You can buy Curaleaf now, but be patient. The ride up could take time, but it could soar into hyperspace any moment, too. Curaleaf boasts 10 buys and one hold at an average price target of $12.14, nearly 50% higher. Buy. Read 3 Cannabis Stocks to go Higher for our full analysis.

Unspecified

Cannabis stocks sold off in the U.S. with many companies burning through cash. Curaleaf should continue to be a leader with cash on the balance sheet and generating cash. It is still building its business. There are challenges in the Cannabis market in the U.S. at the moment. Waiting for more legalization legislation.

BUY

MJ-N down this week He has been long in cannabis. It's been a tough week. Most of this ETF is invested in Canadian stocks. Canopy this week just announced it would issue more shares, which will highly dilute shares. Canopy has been eroding capital quickly. A lot of consolidation needs to happen. The top 3-4 Canadian players are losing market share. Look to U.S. names, instead, where valuations are interesting. Names like Curaleaf are trading at low May 2020 valuations.

COMMENT

A bit of a lottery ticket. Good job expanding in US, strong revenue growth, fairly good cash balance, growing organically. US regulatory environment has not improved. US investment firms won't hold cannabis while still illegal. Tide's gone out on the market. Future is promising, but he can't say when. Will be a leader long term. Investors must decide whether to hold or use tax-loss selling.

PAST TOP PICK

(A Top Pick May 04/21, Down 59%) Derating of secular growth stocks due to rising interest rates. Doing all the right things. Delayed US legislative reform. A victim of the environment. Will be a dominant player in years to come.

Showing 1 to 15 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Curaleaf Holdings Inc (CURA.TO) Frequently Asked Questions

What is Curaleaf Holdings Inc stock symbol?

Curaleaf Holdings Inc is a Canadian stock, trading under the symbol CURA.TO (previously CURA-T on Stockchase) on the Toronto Stock Exchange (CURA-CT). It is usually referred to as TSX:CURA or CURA.TO

Is Curaleaf Holdings Inc a buy or a sell?

In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on CURA.TO (previously CURA-T on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is RISKY. Read the latest stock experts' ratings for Curaleaf Holdings Inc.

Is Curaleaf Holdings Inc a good investment or a top pick?

Curaleaf Holdings Inc was recommended as a Top Pick by Bruce Campbell (2) on 2026-03-09. Read the latest stock experts ratings for Curaleaf Holdings Inc.

Why is Curaleaf Holdings Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Curaleaf Holdings Inc.

Is Curaleaf Holdings Inc worth watching?

Curaleaf Holdings Inc is followed by 119 investors on Stockchase and is a trending stock that is worth watching.

What is Curaleaf Holdings Inc stock price?

On 2026-09-11, Curaleaf Holdings Inc (CURA.TO) stock closed at a price of $13.29.

4.3(3)

Based on 3 expert opinions: 2 buy 1 hold 0 sell

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Curaleaf Holdings Inc (CURA.TO)